Most Viewed Abstracts
1. Report Shows Shift in Starting Salaries for Physicians 2. Use of Antiemetic Agents in Acute Gastroenteritis 3. Gene expression signatures, clinicopathological features, and individualized therapy in breast cancer 4. AHA Guidelines on Cardiac CT for Assessing Coronary Artery Disease 5. Rapid correction of low vitamin D status in nursing home residents
Your Article Summary
Treatment of Very Early Rheumatoid Arthritis With Symptomatic Therapy, Disease-Modifying Antirheumatic Drugs, or Biologic Agents. A Cost-Effectiveness Analysis
Annals of Internal Medicine, 11/03/09
Finckh A et al. – The investigators used available data to estimate the cost–effectiveness of initial treatment strategies for RA. Compared with stepped care, early DMARDs or early biologic agents seem to improve outcomes, but only DMARDs do so at a cost per year of life saved that society typically considers acceptable.
Related Articles
Costs and outcomes for patients with rheumatoid arthritis treated with biological drugs in Sweden: a model based on registry data
Scandinavian Journal of Rheumatology, 11/17/09
Relevance Score: 93%
Review: limited evidence that psychological therapies are of benefit for adults with chronic pain
Evidence-Based Mental Health, 10/28/09
Relevance Score: 92%
Societal cost of rheumatoid arthritis patients in the US
Current Medical Research and Opinion, 11/16/09
Relevance Score: 90%
Good Research Practices for Measuring Drug Costs in Cost Effectiveness Analyses: Issues and Recommendations
Value in Health, 11/11/09
Relevance Score: 89%
Medical care costs of patients with rheumatoid arthritis during the prebiologics period in Japan: a large prospective observational cohort study
Modern Rheumatology, 10/15/09
Relevance Score: 89%
Today in Clinical Pharmacology...keeping you current
Receive free subspecialty "5-minute updates" via email
Effects of metformin with or without supplementation with folate on homocysteine levels and vascular endothelium of women with polycystic ovary syndrome
Diabetes Care, 11/25/09
Low-Density Lipoprotein Cholesterol Reduction and Goal Achievement With Ezetimibe/Simvastatin Versus Atorvastatin or Rosuvastatin in Patients With Diabetes, Metabolic Syndrome, or Neither Disease, Stratified By National Cholesterol Education Program Risk Category
Metabolic Syndrome and Related Disorders, 11/25/09
Chronic Obstructive Pulmonary Disease: Role of Bacteria and Updated Guide to Antibacterial Selection in the Older Patient
Drugs & Aging, 11/25/09
Sponsor
Article Search
Sponsor
Sponsor


See Latest Articles


